January 28, 2025 –— Global Alliance for Regenerative Medicine (GARM), a global pioneer in cutting-edge regenerative and longevity treatments, has officially engaged TWM Capital to advise on and manage its $5 million equity raise as the organization accelerates its international expansion strategy.
With over 11 years of profitability and a renowned reputation in the field of regenerative medicine, GARM is positioned for rapid growth through the establishment of new clinics in premier medical tourism destinations. Many of GARM’s proprietary and exclusive therapies are not available anywhere else in the world, offering groundbreaking alternatives to traditional pharmaceuticals and surgical interventions.
As a testament to its industry leadership, GARM was prominently featured in the 2025 Netflix documentary “Don’t Die,” produced by longevity advocate Bryan Johnson. The film highlights the organization’s visionary contributions to the advancement of patient care and life extension through science-backed regenerative solutions.
To support this next stage of growth, TWM Capital, a leading private capital and strategic advisory firm, has been selected to represent GARM Holdings Inc in overseeing GARM’s international expansion. TWM Capital brings a strong track record of working with high-impact, high-visibility ventures and is recognized for its ability to align sophisticated capital strategies with mission-driven enterprises.
“Working with GARM represents the caliber of client we seek—visionary, ethical, and proven,” said Jeweliet Tangen, Managing Partner at TWM Capital. “GARM is setting new global standards in regenerative care, and we are honored to support their mission by structuring the capital needed to expand their reach and amplify their impact.”
Heather Terry, CEO and co-founder of GARM, added, “Our exclusive treatments and proven track record make GARM an unparalleled leader in the regenerative medicine and longevity fields. This funding will allow us to further expand locations, and therefore, provide additional access for patients to these life-changing therapies and solidify our position at the forefront of the industry.”
Dr. Glenn C. Terry, GARM’s co-founder and Chief Medical Officer, emphasized, “Our mission is to offer transformative, safe, and effective solutions for patients who seek options other than or in addition to conventional surgical and/or pharmaceutical pathways. We are excited to bring our therapies to more people globally.”
Parties interested in learning more about the investment opportunity should contact investors@garmclinic.com.
About GARM
Global Alliance for Regenerative Medicine (GARM) is a leader in regenerative and longevity medicine with over a decade of clinical proven excellence. Known for offering exclusive and effective treatments unavailable elsewhere, GARM combines rigorous safety standards with scientific innovation to enhance patient outcomes across the globe.
About TWM Capital
TWM Capital is a strategic capital advisory firm known for supporting transformative, mission-led ventures with tailored funding solutions and capital strategy. Trusted by high-profile clients, TWM Capital specializes in aligning capital with growth for breakthrough companies.
Disclaimer: TWM Capital is not a licensed broker-dealer. This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.
